Cannabis Science Inc (OTCMKTS:CBIS) has been trading just below its $0.05 established support in recent weeks on moderate volume. CBIS is one of the original pot stocks with a long history of making spectacular moves that knows how to get its story into the national media. The stock saw a spectacular move in the last months of 2016 topping out in Jaunuary of this year.
CBIS operates in the booming MJ sector that continues to grow; according to Forbes North American marijuana sales grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a new report by Arcview Market Research. North American sales are projected to top $20.2 billion by 2021 assuming a compound annual growth rate of 25%. The report includes Canada for the first time as it moves towards implementing legal adult use marijuana.
According to ArcView Market Research, legal cannabis sales jumped by 17% to $5.4 billion in 2015. Now, the industry is expected to grow sales by 25%, to $6.7 billion in total U.S. revenue, in 2016. Additionally, ArcView Market Research predicts that the legal cannabis market will grow to $23.1 billion in total annual sales, by 2020.
Cannabis Science Inc (OTCMKTS:CBIS) works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness.
CBIS initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Several years ago CBIS made a number of acquisitions in the cannabis sector that currently drive future growth. CBIS 2 most important drugs in development are:
The CS-S/BCC-1 drug program was launched in 2011 due to the “apparent success in 4 skin cancer patients who have self-administered cannabinoid based extracts topically to their skin cancers. These patients have experienced shrinking and apparent eradication of their skin cancer lesions.”
The drug CS-TATI-1 aims to target patients with drug-resistant HIV strains. The earliest article I could find relating to the launch of this program was in June 5, 2012, where the company loosely described a mission to “explore the commercial development of Phyto cannabinoid-based therapeutics for drug resistant HIV infection.”
To Find out the inside Scoop on CBIS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Back in March CBIS commented on the recent success of GW Pharmaceuticals in their phase three testing of a CBD-based product designed to treat patients with a rare form of epilepsy.
The successful trials in Europe help pave the way for companies like Cannabis Science to move forward with their own testing in Europe and in the United States. It will also allow for a quicker regulatory process due to more research being made available for regulators and more experience with these types of treatments.
CBIS is working diligently to continue testing and providing limited rollouts for its own CBD-based treatment products in California at the moment. On the heels of GW Pharmaceuticals’ success, the company is more confident than ever in its planned wide-scale rollout, which will include a wider array of near term clinical drug development programs in California, possibly Washington, and the Netherlands.
Earlier this month CBIS announced the publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal Frontiers in Oncology.
On September 19 CBIS announced the full publication of initial research results on using nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids in the world-renowned cancer research journal, Frontiers in Oncology, released today.
“Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids,” addresses drug delivery, and highlights an innovative strategy to transport cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts. The article is an initial result of burgeoning CBIS collaborative work and speaks to a key conclusion from the National Academies of Sciences, Engineering, and Medicine 2017 Report on “The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $111 million market valuation CBIS has little assets or revenues and rising short term debt that has resulted in dilution over the years. But CBIS is an exciting story developing in small caps; the Company is specializing in the development of cannabis-based medicines and has a number of new exciting initiatives in the booming pot sector. CBIS is one of the original pot stocks with a long history of making spectacular moves that knows how to get its story into the national media. CBIS is a great place to be when pot stocks heat up. We will be updating on CBIS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBIS.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CBIS either long or short and we have not been compensated for this article.